Form 13-F position report

SCPHARMACEUTICALS INC

Reported by MORGAN STANLEY

SCPH CUSIP 810648105 Manager CIK 0000895421

Reported 0 shares, down 1,672,825 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q4 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 33 Through Q4 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 375000
2022-03-31 492000
2022-06-30 461000
2022-09-30 608000
2022-12-31 1068172
2023-03-31 10589779
2023-06-30 11834310
2023-09-30 8085322
2023-12-31 1245134
2024-03-31 907214
2024-06-30 962615
2024-09-30 1516903
2024-12-31 6761712
2025-03-31 4960551
2025-06-30 8183446
2025-09-30 9484917
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for SCPHARMACEUTICALS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -1,672,825 (-100.0%) 0 $0 2026-02-13
Q3 2025 Reduced 1,672,825 -475,061 (-22.1%) < 0.01% $9,484,917 2025-11-14
Q2 2025 Added 2,147,886 +261,745 (13.9%) < 0.01% $8,183,446 2025-08-15
Q1 2025 Reduced 1,886,141 -23,947 (-1.3%) < 0.01% $4,960,551 2025-05-15
Q4 2024 Added 1,910,088 +1,577,434 (474.2%) < 0.01% $6,761,712 2025-02-14
Q3 2024 Added 332,654 +111,363 (50.3%) < 0.01% $1,516,903 2024-11-14
Q2 2024 Added 221,291 +40,571 (22.4%) < 0.01% $962,615 2024-08-14
Q1 2024 Reduced 180,720 -17,866 (-9.0%) < 0.01% $907,214 2024-05-15
Q4 2023 Reduced 198,586 -936,993 (-82.5%) < 0.01% $1,245,134 2024-02-13
Q3 2023 Reduced 1,135,579 -25,786 (-2.2%) < 0.01% $8,085,322 2023-11-15
Q2 2023 Reduced 1,161,365 -6,196 (-0.5%) < 0.01% $11,834,310 2023-08-14
Q1 2023 Added 1,167,561 +1,018,583 (683.7%) < 0.01% $10,589,779 2023-05-15
Q4 2022 Added 148,978 +55,689 (59.7%) < 0.01% $1,068,172 2023-02-14
Q3 2022 Reduced 93,289 -2,414 (-2.5%) < 0.01% $608,000 2022-11-14
Q2 2022 Added 95,703 +9,118 (10.5%) < 0.01% $461,000 2022-08-15
Q1 2022 Added 86,585 +11,750 (15.7%) < 0.01% $492,000 2022-05-13
Q4 2021 Added 74,835 +4,742 (6.8%) < 0.01% $375,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

109 managers reported SCPHARMACEUTICALS INC for Q4 2025.

Managers reporting SCPHARMACEUTICALS INC in Q4 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
THE BANK OF NEW YORK MELLON CORPORATION Reduced 0 -85,292 0 $0 23 qtrs
Tejara Capital Ltd Reduced 0 -245,209 0 $0 10 qtrs
ALPINE ASSOCIATES MANAGEMENT INC Reduced 0 -961,065 0 $0 2 qtrs
China Universal Asset Management Co Ltd Reduced 0 -9,342 0 $0 5 qtrs
TUDOR INVESTMENT CORP ET AL Reduced 0 -2,150,000 0 $0 2 qtrs
Russell Investments Group Ltd Reduced 0 -3,743 0 $0 7 qtrs
KING LUTHER CAPITAL MANAGEMENT CORP Reduced 0 -2,128,391 0 $0 12 qtrs
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM Reduced 0 -2,143 0 $0 11 qtrs
Atlantic Edge Private Wealth Management LLC Reduced 0 -425 0 $0 9 qtrs
Rubric Capital Management LP Reduced 0 -5,101,886 0 $0 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2025
Filed
February 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.